Genomics of Human Fibrotic Diseases: Disordered Wound Healing Response.
Genomics of Human Fibrotic Diseases: Disordered Wound Healing Response.
复制标题
DOI：
10.3390/ijms21228590
复制
发表时间：
2020-11-14
影响因子：
5.6
通讯作者：
Tomic-Canic M
中科院分区：
文献类型：
--
作者：
Stone RC;Chen V;Burgess J;Pannu S;Tomic-Canic M
纤维化疾病与全世界近一半的死亡有关，它是对损伤不受控制的伤口愈合反应的结果，其中组织被过量的细胞外基质沉积所取代，导致纤维化和器官功能丧失。大量的全基因组关联研究、微阵列、外显子组测序研究、DNA甲基化阵列、下一代测序和非编码rna谱分析已经在患者来源的纤维化组织中进行，其共同目标是利用基因组学来确定纤维化疾病发展背后的转录网络和生物学途径。在这篇综述中，我们讨论了皮肤、肝脏、肾脏、肺和心脏的纤维化疾病，系统地(1)描述了导致未解决炎症的初始急性损伤，(2)确定了基因组研究已经定义了导致过量基质沉积和纤维化发生的病理基因变化，以及(3)总结了针对基因组研究中发现的促纤维化基因和网络的治疗方法。最终，成功地将基因组研究的观察结果转化为临床结果，将导致新型抗纤维化疗法的发展，从而改善患者的功能生活质量，降低纤维化疾病的死亡率。
Fibrotic disease, which is implicated in almost half of all deaths worldwide, is the result of an uncontrolled wound healing response to injury in which tissue is replaced by deposition of excess extracellular matrix, leading to fibrosis and loss of organ function. A plethora of genome-wide association studies, microarrays, exome sequencing studies, DNA methylation arrays, next-generation sequencing, and profiling of noncoding RNAs have been performed in patient-derived fibrotic tissue, with the shared goal of utilizing genomics to identify the transcriptional networks and biological pathways underlying the development of fibrotic diseases. In this review, we discuss fibrosing disorders of the skin, liver, kidney, lung, and heart, systematically (1) characterizing the initial acute injury that drives unresolved inflammation, (2) identifying genomic studies that have defined the pathologic gene changes leading to excess matrix deposition and fibrogenesis, and (3) summarizing therapies targeting pro-fibrotic genes and networks identified in the genomic studies. Ultimately, successful bench-to-bedside translation of observations from genomic studies will result in the development of novel anti-fibrotic therapeutics that improve functional quality of life for patients and decrease mortality from fibrotic diseases.
登录
查看更多内容
狼疮性肾炎和糖尿病肾病中新型尿液 MicroRNA 生物标志物的鉴定、确认和复制。
影响因子：
9.3
作者：
Cardenas-Gonzalez M;Srivastava A;Pavkovic M;Bijol V;Rennke HG;Stillman IE;Zhang X;Parikh S;Rovin BH;Afkarian M;de Boer IH;Himmelfarb J;Waikar SS;Vaidya VS
通讯作者：
Vaidya VS
影响因子：
5.7
作者：
Brem, Harold;Stojadinovic, Olivera;Tomic-Canic, Marjana
通讯作者：
Tomic-Canic, Marjana
影响因子：
5.3
作者：
Checa, Marco;Ruiz, Victor;Pardo, Annie
通讯作者：
Pardo, Annie
影响因子：
11.1
作者：
Beckerman P;Qiu C;Park J;Ledo N;Ko YA;Park AD;Han SY;Choi P;Palmer M;Susztak K
通讯作者：
Susztak K
DOI：
10.1016/s2213-2600(17)30387-9
发表时间：
2017-11
期刊：
The Lancet. Respiratory medicine
影响因子：
--
作者：
Allen RJ;Porte J;Braybrooke R;Flores C;Fingerlin TE;Oldham JM;Guillen-Guio B;Ma SF;Okamoto T;John AE;Obeidat M;Yang IV;Henry A;Hubbard RB;Navaratnam V;Saini G;Thompson N;Booth HL;Hart SP;Hill MR;Hirani N;Maher TM;McAnulty RJ;Millar AB;Molyneaux PL;Parfrey H;Rassl DM;Whyte MKB;Fahy WA;Marshall RP;Oballa E;Bossé Y;Nickle DC;Sin DD;Timens W;Shrine N;Sayers I;Hall IP;Noth I;Schwartz DA;Tobin MD;Wain LV;Jenkins RG
通讯作者：
Jenkins RG